COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract.
ACE2 receptors and COVID-19
COVID-19
COVID-19 and gastrointestinal pathophysiology
COVID-19 gastrointestinal manifestations
COVID-19 on chronic liver diseases
Gastrointestinal tract
SARS-CoV-2
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
21 Aug 2020
21 Aug 2020
Historique:
received:
06
05
2020
revised:
02
06
2020
accepted:
12
08
2020
entrez:
5
9
2020
pubmed:
5
9
2020
medline:
10
9
2020
Statut:
ppublish
Résumé
The pandemic of coronavirus disease 2019 (COVID-19), caused by a newly identified β-coronavirus (SARS-CoV-2) has emerged as a dire health problem, causing a massive crisis for global health. Primary method of transmission was firstly thought to be animal to human transmission. However, it has been observed that the virus is transmitted from human to human via respiratory droplets. Interestingly, SARS-CoV-2 ribonucleic acid (RNA) has been isolated from patient stools, suggesting a possible gastrointestinal (GI) involvement. Most commonly reported clinical manifestations are fever, fatigue and dry cough. Interestingly, a small percentage of patients experience GI symptoms with the most common being anorexia, diarrhea, nausea and vomiting. The presence of viral RNA in stools is also common and fecal tests can be positive even after negative respiratory samples. The exact incidence of digestive symptoms is a matter of debate. The distribution of Angiotensin converting enzyme type 2 receptors in multiple organs in the body provides a possible explanation for the digestive symptoms' mechanism. Cases with solely GI symptoms have been reported in both adults and children. Viral RNA has also been detected in stool and blood samples, indicating the possibility of liver damage, which has been reported in COVID-19 patients. The presence of chronic liver disease appears to be a risk factor for severe complications and a poorer prognosis, however data from these cases is lacking. The aim of this review is firstly, to briefly update what is known about the origin and the transmission of SARS-CoV-2, but mainly to focus on the manifestations of the GI tract and their pathophysiological background, so that physicians on the one hand, not to underestimate or disregard digestive symptoms due to the small number of patients exhibiting exclusively this symptomatology and on the other, to have SARS-CoV-2 on their mind when the "gastroenteritis" type symptoms predominate.
Identifiants
pubmed: 32884218
doi: 10.3748/wjg.v26.i31.4579
pmc: PMC7445869
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4579-4588Informations de copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Références
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
BMJ. 2020 Apr 28;369:m1710
pubmed: 32345602
J Pathol. 2003 Jul;200(3):282-9
pubmed: 12845623
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
JAMA. 2020 Feb 7;:
pubmed: 32031570
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
Am J Gastroenterol. 2020 May;115(5):766-773
pubmed: 32287140
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
JAMA. 2020 Mar 11;:
pubmed: 32159775
Nat Med. 2020 Apr;26(4):502-505
pubmed: 32284613
Gastroenterology. 2020 May;158(6):1831-1833.e3
pubmed: 32142773
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
J Gen Intern Med. 2020 May;35(5):1545-1549
pubmed: 32133578
Lancet Gastroenterol Hepatol. 2020 May;5(5):434-435
pubmed: 32199469
Clin Gastroenterol Hepatol. 2020 Jun;18(7):1409-1411
pubmed: 32197957
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
Lancet Gastroenterol Hepatol. 2020 May;5(5):425-427
pubmed: 32171057
Mil Med Res. 2020 Mar 13;7(1):11
pubmed: 32169119
Gut. 2020 Jun;69(6):1141-1143
pubmed: 32102928
Gut. 2020 Jun;69(6):1002-1009
pubmed: 32213556
Transfus Med Rev. 2020 Apr;34(2):75-80
pubmed: 32107119
Am J Gastroenterol. 2020 Jun;115(6):942-946
pubmed: 32496741
Pathogens. 2020 Mar 04;9(3):
pubmed: 32143502
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Gastroenterology. 2020 Jul;159(1):81-95
pubmed: 32251668
Gut. 2020 Jun;69(6):997-1001
pubmed: 32241899
Pediatr Pulmonol. 2020 May;55(5):1169-1174
pubmed: 32134205
Gut. 2020 Jun;69(6):973-974
pubmed: 32273292
Gastroenterology. 2020 May;158(6):1518-1519
pubmed: 32142785
J Med Virol. 2020 Apr;92(4):418-423
pubmed: 31967327
Am J Gastroenterol. 2020 Jun;115(6):941-942
pubmed: 32301760
Aliment Pharmacol Ther. 2020 May;51(9):843-851
pubmed: 32222988
Hosp Pediatr. 2020 Jun;10(6):537-540
pubmed: 32265235
Clin Gastroenterol Hepatol. 2020 Jul;18(8):1663-1672
pubmed: 32278065